LCD Reference Article Response To Comments Article

Response to Comments: MolDX: EndoPredict® Breast Cancer Gene Expression Test

A58752

Expand All | Collapse All

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	States
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05101 - MAC A	J - 05	Iowa
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	05102 - MAC B	J - 05	Iowa
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05201 - MAC A	J - 05	Kansas
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	05202 - MAC B	J - 05	Kansas
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05301 - MAC A	J - 05	Missouri - Entire State
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	05302 - MAC B	J - 05	Missouri - Entire State
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05401 - MAC A	J - 05	Nebraska
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	05402 - MAC B	J - 05	Nebraska
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	05901 - MAC A	J - 05	Alabama Alaska Arizona Arkansas California - Entire State Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Mississippi Missouri - Entire State Montana Nebraska Nevada New Hampshire New Jersey New Mexico North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin Wyoming
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	08101 - MAC A	J - 08	Indiana
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	08102 - MAC B	J - 08	Indiana
Wisconsin Physicians Service Insurance Corporation	MAC - Part A	08201 - MAC A	J - 08	Michigan
Wisconsin Physicians Service Insurance Corporation	MAC - Part B	08202 - MAC B	J - 08	Michigan

Article Information

General Information

Article ID
A58752

Article Title
Response to Comments: MolDX: EndoPredict® Breast Cancer Gene Expression Test

Article Type
Response to Comments

Original Effective Date
07/04/2021

Retirement Date
N/A

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Article Guidance

Article Text

The comment period for the MolDX: EndoPredict Breast Cancer Gene Expression Test DL37663 Local Coverage Determination (LCD) began on 04/23/20 and ended on 07/07/20. The notice period for L37663 begins on 05/20/21 and will become effective on 07/4/21. The comments below were received from the provider community.

Thank you for the comments.

Response To Comments

Number	Comment	Response
1	The following comment was submitted to Palmetto GBA and Noridian: We appreciate the opportunity to submit comments on draft LCDs for MolDX: EndoPredict Breast Cancer Gene Expression Test which propose non-coverage of the Endopredict test when used to aid in decision-making for extended endocrine therapy (EET) in patients with breast cancer. We request your review of the data presented below and consideration of the attached suggested revisions to the draft LCD, to allow coverage of EndoPredict in women with node-negative, hormone-receptor positive, HER2-negative breast cancer when considering extension of endocrine therapy beyond five years. Executive Summary: Societal guidelines, i.e. ASCO, clearly state that recurrence risk, specifically, should be considered when deciding about EET for women with node-negative, hormone-receptor positive breast cancer and that women with low-risk node-negative tumors should not uniformly be offered extended therapy (Recommendation 1).¹ Furthermore, the ASCO guideline states that genomic signatures, including EndoPredict, are sufficiently robust to reasonably inform this clinical decision. In published analyses of three randomized trial cohorts, ABCSG-6&8 and TransATAC, EndoPredict was shown to identify a group of node-negative patients who could safely forgo EET based on sufficiently low risk of distant recurrence (DR) by 10 years or 15 years.^2,3 In a head-to-head comparison, EndoPredict compared similarly to Breast Cancer Index (BCI) for predicting DR.³ The BCI test currently has MolDX coverage for selecting patients with hormone receptor-positive, HER2-negative, node-negative disease who may safely forgo extended endocrine therapy. Guidelines The draft LCD appropriately acknowledges that current professional society guidelines suggest consideration of EET for certain subsets of patients with breast cancer.^1,4 The ASCO Clinical Practice Guideline on Adjuvant Endocrine Therapy for Women with Hormone Receptor-Positive Breast Cancer is specifically mentioned, which is understandable given the recent publication of a focused update about the optimal duration of aromatase inhibitor (AI) treatment .¹ However, we believe the statement, “ASCO Guidelines suggest using clinical criteria, including assessing tolerability, for determining which patients should be given EET” lacks important details from the guideline about incorporating the risk of recurrence. An accurate predictor of recurrence risk provides a key piece of information which patients can use in their decision-making, since some women will prefer to avoid EET (and its associated chance of side effects and complications) if their DR risk is predicted to be low. The ASCO focused update addresses postmenopausal women who have received aromatase inhibitor-(AI) based therapy as part of their initial 5 years of adjuvant treatment. Following an evidence review of the efficacy of additional ongoing AI therapy, ASCO describes the 2-4% improvement in disease-free survival (based on a relative reduction in recurrence risk of 15-20%) as “measurable but modest”. They go on to conclude that lower-risk patients will garner less benefit on average. When detailing Recommendation 1 in their guideline [page 434], ASCO states, “Many women with node-negative breast cancer are potential candidates for and may be offered extended AI therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors. The use of the word ‘many’ underscores that not all women with node-negative breast cancer will benefit from extended AI therapy. In women with node negative breast cancers, T stage, grade, and genomic signature [emphasis added] are all known to serve as prognostic markers for risk of recurrence after 5 years of endocrine therapy. The Expert Panel favored extended AI treatment among higher-risk, node-negative patients, including women with stage T2/T3 tumors and T1c tumors with higher-risk prognostic factors based on the assumption that a higher residual risk of recurrence will translate into a larger clinical benefit with extended therapy.” Finally, ASCO’s expert panel “believed that retrospective findings on the importance of established prognostic factors, including stage, grade, and genomic signatures (Table 4), for both early and late recurrence have become sufficiently robust that a clinical risk stratification that reflected these prognostic factors could reasonably be used to inform the clinical decision about extended therapy with AI treatment” [page 435]. Note that Table 4 in the guideline lists prognostic factors for recurrence after 5 years of adjuvant endocrine therapy, including EndoPredict. EndoPredict’s performance in the late (5-10 and 5-15 year) time periods among women with hormone-receptor positive, HER2-negative, node-negative breast cancer. The draft LCD Analysis of Evidence (Rationale for Determination) questions the ability of EndoPredict to delineate risk of late recurrence and contribute to decision-making about the use of EET in node-negative patients. In the combined ABCSG-6&8 cohorts, Filipits et al. showed a very low 5-10-year DR rate of 2.1% (CI 0.9-3.3%) for node -negative patients determined to be low risk by EndoPredict and who were recurrence-free at 5 years (Supplementary Table S5).² The corresponding 5-10 year DR rate for the high-risk group was almost 3-fold higher than that for the low risk group; yet still rather modest– 5.9% (95% CI 2.2-9.5%) – because some of the high-risk patients had not yet experienced a recurrence. The difference in 5-10 year DR rates between the node-negative EPclin Low vs EPclin High groups at 5-10 years was statistically significant (HR=3.13, p=0.0077, not shown in publication), even though both groups had DR rates of <10% during this time period. In a cohort with a lower baseline risk (as in the ABCSG-6&8 cohorts, in which 67% had T1 tumors and 89% had Grade 1/2 disease), the difference in DR rates between the low- and high-risk groups may become more apparent 10-15 years after diagnosis. Although based on fewer patients, analysis of the data from the 5-15 time period showed larger and statistically significant differences in DR rates between EPclin Low vs High groups (Figure 2B and Table S5).² Evaluation of this time period is clinically important, as the risk of recurrence is known to persist out to 20 years post-diagnosis. Although some patients experienced DR in years 5-10, a similar number experienced DR in years 10-15 as well, primarily in the high-risk group. For the 5-15 year time period, node-negative patients determined to be low risk by EndoPredict continued to experience a low DR rate of 3.1% (95% CI 1.5-4.8%), while patients determined to be high risk by EndoPredict had a significantly higher DR rate of 15.1% (95% CI 4.0-24.9%) (HR=3.77, p<0.0001). These data clearly demonstrate that patients with EPclin Low scores continue to have a very low risk of late DR at 15 years and cannot be discounted on the basis that the absolute difference from the EPclin High risk group at 10 years was not as large. Furthermore, Sestak et al. (2018) also provides data that is relevant to the use of EndoPredict in making decisions about EET.³ The performance of 6 different breast cancer gene expression profile tests was compared in a head-to-head analysis using archived tumors from patients in the TransATAC randomized controlled trial. Importantly, Sestak et al. included BCI, which has MolDX coverage for use in selecting patients with N0 disease who may safely forgo EET. In a subgroup analysis of patients that had not recurred in the first 5 years, both EndoPredict and BCI similarly were able to discriminate 5-10 year DR risk among node-negative patients with low vs. high scores. As shown in the table below, the EPclin 5-10-year DR rate was <5% in the low risk group and >10% in the high risk group. (Compared to ABCSG-6&8, the TransATAC cohort was generally higher risk, with 18% of patients having grade III tumors.) Question raised during Noridian Open Meeting on June 2 During the Noridian Open Meeting on June 3, Dr. Clark posed a question about the following sentence (first paragraph of the Summary of Evidence) and asked for input from stakeholders: “Approximately 54% of early-stage breast cancers are estrogen receptor (ER)-positive and HER2-negative, leading to treatment with adjuvant endocrine therapy (e.g., tamoxifen or aromatase inhibitors) that significantly improves prognosis.^2,3” He questioned the discrepancy with a similar phrase that appears in the LCD for the Breast Cancer Index test, which states that ~80% of breast cancers are hormone-receptor positive. We reviewed the reference associated with the sentence above (Howlader et al. 2014), which clearly states that 72.7% of breast cancers are hormone-receptor-positive, HER2-negative. The 54% figure in the draft LCD documents appears to be an error; we have noted this in the suggested revisions in our attached document. We cannot comment on the origin of the 80% figure, as the associated reference (Pritchard et al 2017) does not appear to provide such information. Summary EndoPredict has been shown to reliably identify a group of hormone-receptor positive, HER2-negative, node-negative patients who are recurrence-free at five years and who have sufficiently low risk of DR by 10 years or 15 years that they could safely forgo EET. Societal guidelines support the use of genomic signatures to provide individualized recurrence risk information that aids in decision-making about EET, especially in node-negative patients who should not routinely be offered extended therapy if low-risk. We appreciate your review of the data presented herein and request that you provide coverage for EndoPredict in women with node-negative, hormone-receptor positive, HER2-negative breast cancer when considering extension of endocrine therapy beyond five years.	Thank you for your comments. We believe the clinical utility of this test for determining which patients would benefit from EET is not clear based on the data. This test is indicated in node-negative and 1-3 node-positive patients. First, the data presented in Filipits et al. for 1-3 node-positive patients was not significant for the period studied (5-15 years), and the difference in DRFR was 84% vs 87% between the EPclin high and low group. While the difference between EPclin high and low groups are significant in node–negative patients for the duration of the study (96% vs 85% DRFR), a subset analysis of the best supported data shows that 5-10 years after ET therapy there is little difference in the performance of these patients; neither the EPclin high or low group would be defined as “high risk” (>10% risk of recurrence), and the difference in DRFR between these two groups is 97.9% vs. 94.1%. Based on this study, this contractor does not believe there is sufficient evidence that this test can clearly delineate patients who can benefit from EET (whose benefits are already known to be ‘modest’).
2	The following comment was submitted to Palmetto GBA and Noridian: I am a private practice medical oncologist in Idaho Falls ID where I have practiced breast oncology for the past seventeen years. I have seen the advent of extended adjuvant hormonal therapy and the difficulty in decision making that can ensue given the modest benefit and sometimes significant toxicity. The best example would be a woman who wants to be as “aggressive as possible” in treating her cancer but is having significant side effects from five years of an aromatase inhibitor. It has been very useful to have a biomarker in these instances to guide decision making. On the basis of the data presented by Sestak and Buss in JAMA Oncol. April 1, 2018, I have selected the EndoPredict test to use in my practice. As you know, EndoPredict performed similarly to BCI in this setting, a test for which a positive coverage determination has already been made. I believe EndoPredict to be the superior test insofar as it can extend to 15 year risk of recurrence rather than only 10 years. I hope that you can reconsider coverage of EndoPredict for this indication in the Medicare population.	Thank you for your comments. We have addressed them in the policy.

Coding Information

Bill Type Codes

Code	Description
Please accept the License to see the codes.

Revenue Codes

Code	Description
Please accept the License to see the codes.

CPT/HCPCS Codes

Expand All | Collapse All

Please accept the License to see the codes.

ICD-10-CM Codes that Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-PCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

Additional ICD-10 Information

Bill Type Codes

Code	Description
Please accept the License to see the codes.

Revenue Codes

Code	Description
Please accept the License to see the codes.

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion
			N/A	N/A

Non-Excluded CPT/HCPCS Ended Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion

Revision History Information

N/A

Associated Documents

Updated On	Effective Dates	Status
05/10/2021	07/04/2021 - N/A	Currently in Effect	You are here

Keywords

N/A

Read the Article Disclaimer

License Agreements
American Medical Association Current Procedural Terminology
American Dental Association Current Dental Terminology
American Hospital Association NUBC UB-04

Please review the licensing information below and indicate your agreement and acceptance.

License for Use of Current Procedural Terminology (CPT)

End User Point and Click Agreement: CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

You, your employees, and agents are authorized to use CPT only as agreed upon with the AMA internally within your organization within the United States for the sole use by yourself, employees, and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza, 330 Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/go/cpt http://www.ama-assn.org/go/cpt.

Applicable FARS\DFARS Restrictions Apply to Government Use.

This product includes CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, AMA Plaza, 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of FAR 52.227-14 (December 2007) and/or subject to the restricted rights provisions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CPT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material contained on this page. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

License For Use of Current Dental Terminology (CDT^TM)

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood, and agreed to all terms and conditions set forth in this agreement.

If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org/ http://www.ADA.org/.

Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use.

Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.

ADA DISCLAIMER OF WARRANTIES AND LIABILITIES

CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values, or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The ADA is a third-party beneficiary to this Agreement.

CMS DISCLAIMER

The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead, you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

License For Use of National Uniform Billing Committee (NUBC) UB-04

These materials contain NUBC Official UB-04 Specifications (UB-04 Data), which is copyrighted by the American Hospital Association (AHA).

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN. IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use UB-04 Data only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of UB-04 Data is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this Agreement. You acknowledge that the AHA holds all copyright, trademark, and other rights in UB-04 Data. You shall not remove, alter, or obscure any AHA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including, by way of illustration and not by way of limitation, making copies of UB-04 Data for resale and/or license, transferring copies of UB-04 Data to any party not bound by this agreement, creating any modified or derivative work of UB-04 Data, or making any commercial use of UB-04 Data. License to use UB-04 Data for any use not authorized herein must be obtained through the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois, 60606. Applications are available at the NUBC website, http://www.nubc.org/ http://www.nubc.org/.
The UB-04 Data included in this product is commercial technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation, as applicable, which was developed exclusively at private expense by the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois 60606. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.
AHA DISCLAIMER OF WARRANTIES AND LIABILITIES. UB-04 Data is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The sole responsibility for the software, including any UB-04 Data and other content contained therein, is with the Medicare/Medicaid Contractor or the CMS; and no endorsement by the AHA is intended or implied. The AHA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The AHA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the AHA, the copyright holder. Any questions pertaining to the license or use of the UB-04 Data should be addressed to the AHA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE UB-04 DATA. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Submit Feedback/Ask a Question

Response to Comments: MolDX: EndoPredict® Breast Cancer Gene Expression Test

Document Note

Note History

Contractor Information

Article Information

General Information

CMS National Coverage Policy

Article Guidance

Response To Comments

Coding Information

Bill Type Codes

Please accept the License to see the codes.

Revenue Codes

Please accept the License to see the codes.

CPT/HCPCS Codes

Please accept the License to see the codes.

CPT/HCPCS Modifiers

Group 1

ICD-10-CM Codes that Support Medical Necessity

Group 1

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

ICD-10-PCS Codes

Group 1

Additional ICD-10 Information

Bill Type Codes

Please accept the License to see the codes.

Revenue Codes

Please accept the License to see the codes.

Other Coding Information

Group 1

Coding Table Information

Revision History Information

Associated Documents

Keywords

Page Help for Article - Response to Comments: MolDX: EndoPredict® Breast Cancer Gene Expression Test (A58752)

Introduction

Finding a specific code

More information

Printing a Document to PDF

Get email updates

CMS & HHS WEBSITES

HELPFUL LINKS

RSS FEEDS